Trial Profile
A retrospective cohort study to evaluate the fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Dec 2015
Price :
$35
*
At a glance
- Drugs Fosaprepitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting; Emesis
- Focus Adverse reactions
- 17 Dec 2015 New trial record